紫杉醇涂层球囊冠状动脉血运重建后的生存分析:随机对照试验荟萃分析
该荟萃分析纳入26项随机对照试验共4590例患者,比较紫杉醇药物涂层球囊(DCB)与非DCB器械治疗冠状动脉支架内再狭窄或原发病变的生存结局。结果显示DCB未增加全因死亡风险,3年随访时全因死亡和心源性死亡均显著低于对照组。
要点
- 紫杉醇DCB冠状动脉介入未增加全因死亡风险,与周围动脉报道不同。
- 3年随访DCB组全因死亡显著低于对照组(RR 0.73,95%CI 0.53-1.00,P=0.047)。
- 心源性死亡也显著降低(RR 0.53,95%CI 0.33-0.85,P=0.009)。
核心结论
- 紫杉醇DCB用于冠状动脉疾病治疗未增加死亡风险,3年随访时全因死亡和心源性死亡均显著低于对照治疗。
研究设计与样本
- 检索PubMed、Web of Science和Cochrane图书馆数据库,纳入2006至2019年发表的26项随机对照试验,共4590例患者。
- 比较DCB与非DCB器械(常规球囊血管成形术、裸金属支架或药物洗脱支架)治疗冠状动脉支架内再狭窄或原发病变。
- 主要结局为全因死亡,风险估计以风险比(RR)及95%置信区间(CI)报告。
主要发现
- 随访6至12个月,全因死亡率无显著差异,DCB组数值上更低(RR 0.74;95%CI 0.51-1.08;P=0.116)。
- 2年随访(n=1477,8项RCT)两组死亡风险相似(RR 0.84;95%CI 0.51-1.37;P=0.478)。
- 3年随访(n=1775,9项RCT)DCB组全因死亡显著低于对照组(RR 0.73;95%CI 0.53-1.00;P=0.047),需治疗人数为36以预防1例死亡。
- 心源性死亡也显著降低(RR 0.53;95%CI 0.33-0.85;P=0.009)。
临床怎么用
- 对于冠状动脉支架内再狭窄或原发病变,紫杉醇DCB治疗未显示死亡风险增加,3年随访时全因死亡和心源性死亡均低于对照治疗。
局限性
- 随访期间存在失访患者,需在不同时间点观察失访人数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug-coated balloons (DCBs) are accepted treatment strategies for coronary in-stent restenosis and are under clinical investigation for lesions without prior stent implantation. A recently published meta-analysis suggested an increased risk of death associated with the use of paclitaxel-coated devices in the superficial femoral artery. The reasons are incompletely understood as potential underlying pathomechanisms remain elusive, and no relationship to the administered dose has been documented. OBJECTIVES: The purpose of this analysis was to investigate the available data on survival after coronary intervention with paclitaxel-coated balloons from randomized controlled trials (RCTs). METHODS: PubMed, Web of science, and the Cochrane library database were searched, and a meta-analysis from RCT was performed comparing DCB with non-DCB devices (such as conventional balloon angioplasty, bare-metal stents, or drug-eluting stents) for the treatment of coronary in-stent restenosis or de novo lesions. The primary outcome was all-cause death. The number of patients lost to follow-up was observed at different time points. Risk estimates are reported as risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: A total of 4,590 patients enrolled in 26 RCTs published between 2006 and 2019 were analyzed. At follow-up of 6 to 12 months, no significant difference in all-cause mortality was found, however, with numerically lower rates after DCB treatment (RR: 0.74; 95% CI: 0.51 to 1.08; p = 0.116). Risk of death at 2 years (n = 1,477, 8 RCTs) was similar between the 2 groups (RR: 0.84; 95% CI: 0.51 to 1.37; p = 0.478). After 3 years of follow-up (n = 1,775, 9 RCTs), all-cause mortality was significantly lower in the DCB group when compared with control treatment (RR: 0.73; 95% CI: 0.53 to 1.00; p = 0.047) with a number needed to treat of 36 to prevent 1 death. A similar reduction was seen in cardiac mortality (RR: 0.53; 95% CI: 0.33 to 0.85; p = 0.009). CONCLUSIONS: In this meta-analysis, the use of paclitaxel DCBs for treatment of coronary artery disease was not associated with increased mortality, as has been suggested for peripheral arteries. On the contrary, use of coronary paclitaxel-coated balloons was associated with a trend toward lower mortality when compared with control treatments.
引用
- Scheller B, Vukadinovic D, Jeger R, et al. Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. J Am Coll Cardiol. 2020. PMID: 32138961. doi:10.1016/j.jacc.2019.11.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。